Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 1, 2025The International Journal of NeuropsychopharmacologyOpen Access

An Overview of the Project Exploring Gene-Drug Pairs in Dose Guidance of Antidepressants and Antipsychotics

View Full Paper
Ask AI
Bookmark
Share

Authors

RWRoos van WestrhenenAYAllan H. Young

Discussion

Loading...

Member takes

Overview

Clinical study assesses pharmacogenetics' role in medication success for psychiatric disorders, indicating a path toward personalized care.

Key Points

  • Pharmacogenetics improves medication success rates for psychiatric patients, aiming for personalized treatment regimens.
  • Over 11,000 mood disorder patients from primary care sources provide data on medication effectiveness.
  • Multi-center clinical study examines biobank relationships, guiding physicians in drug selection and dosing.
  • Algorithm development seeks to tailor antidepressant and antipsychotic treatments based on individual patient factors.

Cite This Study

Westrhenen et al. (2025) studied this question.

synapsesocial.com/papers/68af2ee5cf1dd9ea359e67ffhttps://doi.org/10.1093/ijnp/pyaf052.389
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1561. PHARMACOGENETIC-SUPPORTED PRESCRIBING FOR KIDS WITH MENTAL HEALTH CONDTIONS2025
  2. 2Psychotropic pharmacogenetics in adult populations: From basic science to clinical trials and health economics – An evidence-based overview for decision makers2025
  3. 3177. A GENETICALLY INFORMED APPROACH TO ANTIDEPRESSANT PRESCRIPTION FOR YOUTH WITH MAJOR DEPRESSIVE DISORDER2025
  4. 4Evidence level for pharmacogenetic testing in antidepressant treatment: a systematic review2025 · 3 citations
  5. 5Real‐World Characterization of Psychiatric Pharmacogenomic Test Ordering and Clinical Relevance in Adults and Children2025